In recent years,the post-translational modification in epigenetics has drawn the attention of the researchers,and is expected to become the important direction for tumor pharmacology research in future.Chinese herbal medicine has the advantages of less side effects and better efficacy,and has shown good prospects in the research of prevention and treatment of colorectal cancer.This paper outlined the types of post-translational modifications in epigenetics and their roles in the progression of colorectal cancer,and explored the possible mechanisms of single Chinese herbal medicine and Chinese herbal compounds in the treatment of colorectal cancer by influencing post-translational modifications.In the progression of colorectal cancer,the post-translational modifications such as ubiquitination,ubiquitination-like,acetylation,crotonylation and glycylation were involved.The Chinese medicinal active ingredients from Coptidis Rhizoma,Euodiae Fructus,Scutellariae Radix,Curcumae Longae Rhizoma,etc.,and Chinese herbal compounds of Yiliu Decoction and Teng Long Buzhong Decoction have all shown certain effects for the prevention and treatment of colorectal cancer by participating in post-translational modifications.The in-depth exploration of the therapeutic mechanism of Chinese herbal medicine in the prevention and treatment of colorectal cancer and the development of new Chinese medicinal preparations from the perspective of post-translational modification are expected to become a new direction for the future research on the mechanism of anti-colorectal cancer and on the application of anti-cancer agents.

Aim To investigates whether sphingosine-1-phosphate(S1P)regulates the expression of mitochon-drial calcium uniporter(MCU)via the sphingosine-1-phosphate receptor/proline-rich tyrosine kinase 2(S1PR/Pyk2)sig-naling pathway,thereby reducing oxidative stress-induced mitochondrial damage and inhibiting mitochondria-related apopto-sis.Methods Human umbilical vein endothelial cells(HUVEC)were subjected to oxidative damage using hydrogen peroxide(H2O2)as a model.Different concentrations of S1P were applied to the oxidative damaged HUVEC.Addi-tionally,the S1PR1 agonist SEW2871,the S1PR1 inhibitor W146,and the Pyk2 inhibitor PF-562271 were used to explore the specific mechanism of S1P action.Results S1P treatment significantly alleviated oxidative damage in HUVEC and was accompanied by an increase in S1PR1 expression(P<0.05),while S1PR3 expression remained unchanged.Mean-while,the expression levels of Pyk2 and MCU decreased(P<0.05).SEW2871 further reduced mitochondrial damage,whereas W146 exacerbated it(P<0.05).Furthermore,the application of the Pyk2 inhibitor PF-562271 also reduced H2O2-induced mitochondrial damage(P<0.05),further confirming the role of Pyk2 in this process.Conclusion S1P reduces H2O2-induced mitochondrial damage and inhibits mitochondria-related apoptosis in HUVEC by suppressing Pyk2 expression via S1PR1.

Objective To investigate the patterns of changes in biochemical factors(IL-1β and TGF-β1)and biophysical factors within the periodontal ligament microenvironment at different stages of periodontitis development.Methods Periodontitis models at different stages of development(early and late stages)were constructed in rats.The changes in the periodontal ligament microenvironment were determined by detecting biochemical factors((IL-1β and TGF-β1)and changes in periodontal ligament stiffness.Results Regarding biochemical factors,the growth factor TGF-β1 was at a high level in the early stage of periodontitis,while the inflammatory factor(IL-1β was slightly increased compared to the normal state,but expressed at a low level.As the inflammation progressed,the expression of TGF-β1 was suppressed and significantly decreased in the late stage of periodontitis(late stage:11.34±2.91 vs.early stage:20.41±2.64,P＜0.01).In contrast,the expression of(IL-1βsignificantly increased(late stage:18.77±3.36 vs.early stage:8.24±1.47,P＜0.01).Regarding biophysical factors,the stiffness of the periodontal ligament and the expression of the key protein integrin αv β3 in the mechanical signaling pathway gradually decreased with the development of periodontitis.Additionally,the osteogenic differentiation capacity of stem cells significantly decreased in the late stage of periodontitis(late stage:12.47±2.83 vs.early stage:21.15±4.38,P＜0.05).Conclusion TGF-β1 may play a role in promoting periodontal tissue repair and maintaining physiological stability in normal and early stages of periodontitis,while the increased expression of(IL-1β in the late stage of periodontitis may inhibit the osteogenic differentiation of stem cells,leading to bone loss.Biophysical factors,including matrix stiffness and integrin αvβ3 expression,gradually decrease with the progression of periodontitis,potentially affecting bone tissue repair.

Aim To investigates whether sphingosine-1-phosphate(S1P)regulates the expression of mitochon-drial calcium uniporter(MCU)via the sphingosine-1-phosphate receptor/proline-rich tyrosine kinase 2(S1PR/Pyk2)sig-naling pathway,thereby reducing oxidative stress-induced mitochondrial damage and inhibiting mitochondria-related apopto-sis.Methods Human umbilical vein endothelial cells(HUVEC)were subjected to oxidative damage using hydrogen peroxide(H2O2)as a model.Different concentrations of S1P were applied to the oxidative damaged HUVEC.Addi-tionally,the S1PR1 agonist SEW2871,the S1PR1 inhibitor W146,and the Pyk2 inhibitor PF-562271 were used to explore the specific mechanism of S1P action.Results S1P treatment significantly alleviated oxidative damage in HUVEC and was accompanied by an increase in S1PR1 expression(P<0.05),while S1PR3 expression remained unchanged.Mean-while,the expression levels of Pyk2 and MCU decreased(P<0.05).SEW2871 further reduced mitochondrial damage,whereas W146 exacerbated it(P<0.05).Furthermore,the application of the Pyk2 inhibitor PF-562271 also reduced H2O2-induced mitochondrial damage(P<0.05),further confirming the role of Pyk2 in this process.Conclusion S1P reduces H2O2-induced mitochondrial damage and inhibits mitochondria-related apoptosis in HUVEC by suppressing Pyk2 expression via S1PR1.

Objective To investigate the patterns of changes in biochemical factors(IL-1β and TGF-β1)and biophysical factors within the periodontal ligament microenvironment at different stages of periodontitis development.Methods Periodontitis models at different stages of development(early and late stages)were constructed in rats.The changes in the periodontal ligament microenvironment were determined by detecting biochemical factors((IL-1β and TGF-β1)and changes in periodontal ligament stiffness.Results Regarding biochemical factors,the growth factor TGF-β1 was at a high level in the early stage of periodontitis,while the inflammatory factor(IL-1β was slightly increased compared to the normal state,but expressed at a low level.As the inflammation progressed,the expression of TGF-β1 was suppressed and significantly decreased in the late stage of periodontitis(late stage:11.34±2.91 vs.early stage:20.41±2.64,P＜0.01).In contrast,the expression of(IL-1βsignificantly increased(late stage:18.77±3.36 vs.early stage:8.24±1.47,P＜0.01).Regarding biophysical factors,the stiffness of the periodontal ligament and the expression of the key protein integrin αv β3 in the mechanical signaling pathway gradually decreased with the development of periodontitis.Additionally,the osteogenic differentiation capacity of stem cells significantly decreased in the late stage of periodontitis(late stage:12.47±2.83 vs.early stage:21.15±4.38,P＜0.05).Conclusion TGF-β1 may play a role in promoting periodontal tissue repair and maintaining physiological stability in normal and early stages of periodontitis,while the increased expression of(IL-1β in the late stage of periodontitis may inhibit the osteogenic differentiation of stem cells,leading to bone loss.Biophysical factors,including matrix stiffness and integrin αvβ3 expression,gradually decrease with the progression of periodontitis,potentially affecting bone tissue repair.

Objective:To investigate the treatment options for multiple myeloma patients with central nervous system involvement (CNS-MM) , as well as their clinical characteristics and prognostic factors.Methods:Between January 2011 and January 2022 our center diagnosed 18 people with CNS-MM. A retrospective analysis was done on the clinical information from the initial diagnosis and central nervous system involvement, and it was compared to 1∶3 matched newly diagnosed MM from the same period. Analysis was done on the clinical characteristics and survival rates of the two groups.Results:In patients with CNS-MM, the median time of onset was 14.2 (0.9-79.6) months and the median overall survival (OS) was 30.5 months from initial diagnosis and only 3.8 months in patients after CNS involvement. The CNS-MM patients showed more IgD type ( P=0.010) , severer anemia ( P=0.014) , a higher proportion of bone marrow plasma cells ( P=0.013) , more extramedullary lesions ( P=0.001) , and increased lactic dehydrogenase (LDH) ( P=0.009) when compared to the control group. Lenalidomide or pomalidomide-based combinations had higher rates of hematology and CNS remission than bortezomib or daratumumab-based regimens (75.0% vs 16.7% , P=0.019) . Patients who received IMiD-based regimens and had 2 high-risk factors at initial diagnosis (high LDH and extramedullary lesions) had a significantly lower incidence of CNS-MM ( P=0.026) . At the initial diagnosis, LDH ( P=0.008, HR=7.319, 95% CI 1.663-32.219) and extramedullary lesions ( P=0.006, HR=8.054, 95% CI 1.828-35.486) were independent risk factors for the occurrence of CNS-MM. Conclusion:Patients with CNS-MM had a poor prognosis. Patients with high LDH or extramedullary lesions at the time of the initial diagnosis are more likely to have CNS-MM. The prognosis of this patient may be improved by immunoregulator-based therapy.

Objective:To explore the effect of venetoclax-based therapy on relapsed/refractory multiple myeloma (MM) patients harboring t(11;14).Methods:The data of a relapsed/refractory MM patient harboring t(11;14) treated with venetoclax-based regimen admitted to Shanghai Changzheng Hospital in June 2019 was retrospectively analyzed and the literatures were reviewed.Results:The relapsed/refractory MM patient harboring t(11;14) had progression of disease after 3 lines of therapies, and then was treated with the selective bcl-2 inhibitor venetoclax combined with daratumumab and dexamethasone. As a result, the patient achieved partial remission and better hemogram recovery. The Eastern Cooperative Oncology Group (ECOG) score of physical status decreased from 3 to 1, and the quality of life was improved significantly.Conclusions:The relapsed/refractory MM patients harboring t(11;14) could benefit from venetoclax-based therapy. In the future, the safety, sensitivity and other performances of venetoclax in the treatment of MM should be further explored.

Objective:To investigate the efficacy and safety of daratumumab in relapsed and refractory multiple myeloma (RRMM) .Methods:The clinical characteristics, adverse reactions, efficacy, and prognosis of 46 patients with RRMM treated with daratumumab in Shanghai Changzheng Hospital from September 2017 to March 2020 were retrospectively analyzed.Results:All patients were treated with daratumumab-based regimen: 8 in the Dd group, 35 in the DRd group, and 3 in the DVd group. With a median follow-up of 9.6 months, the overall response rate (ORR) was 75% [complete remission (CR) rate 18.2% ] among the 44 patients available for evaluation. The ORRs of patients resistant to bortezomib, lenalidomide, and both were 70.6% , 69.2% , and 63.6% , respectively. The CR rates of patients resistant to bortezomib, lenalidomide, and both were 17.6% , 11.5% , and 13.6% , respectively. No significant difference was observed in ORR and CR rates among the three groups. The ORRs of the DRd, DVd, and Dd groups were 85.3% , 66.7% , and 28.6% , respectively ( P=0.007) . The median PFS of 46 patients was 8.9 months, the median OS was not reached, and the 1-year OS rate was 74% . The median PFS and OS in the DRd group were longer than those in the Dd group (PFS: 14.4 months vs 2.0 months; OS: not reached vs 5.2 months) . After treatment with daratumumab, neutropenia is the most common hematological adverse reaction above grade 3. Non-hematological adverse reactions are mainly infusion-related adverse reactions and infections. Prognostic analysis showed that patients with extramedullary invasion had shorter PFS and OS compard with patients without extramedullary invasion (PFS: 5.7 vs 14.4 months, P=0.033; OS: 6.3 months vs not reached, P=0.029) . The OS of patients with an ECOG score of 3-4 was significantly shorter than patients with an ECOG score of 1-2 (5.9 months vs not reached, P=0.004) . Conclusion:Daratumumab-based regimens have good efficacy and safety in the treatment of RRMM.

Objective:To explore the relationship between death indicators and unplanned return indicators on healthcare quality evaluation.Methods:A total of 836 976 medical record data were collected from 31 tertiary public general hospitals in a diagnosis-related groups(DRG) data platform in 2017. Multiple death indices(low and low-risk risk group mortality, high-risk group mortality, crude mortality, and risk adjusted mortality) and unplanned return indices(31-day unplanned readmission rate and 31-day unplanned return to surgery rate) were calculated. Pearson′s correlation coefficient was used to examine the relationships among those indices.Results:Death indicators were correlated with each other, but the unplanned readmission rate was not correlated with the unplanned reoperation rate( r=0.305). There was no correlation between unplanned re-entry rate and death rate. The correlation coefficients were as follows: unplanned readmission rate versus low and low-risk group mortality( r=-0.227), versus high-risk group mortality( r=-0.098), versus actual mortality( r=-0.130), versus risk adjusted mortality( r=0.010); unplanned reoperation rate versus low and low-risk group mortality( r=0.105), versus high-risk group mortality( r=0.030), versus actual mortality( r=-0.004), versus risk adjusted mortality( r=-0.141). Conclusions:The indicators of death and the indicators of unplanned return are not the same in terms of actual management technology and evaluation effect. They are complementary to each other and can form an ideal combination of quality evaluation indicators.

Objective: To investigate the effects of sinomenine on brain edema and the expression of aquaporin 4 (AQP-4) and aquaporin 5 (AQP-5) in rats with acute brain injury. Methods: According to random number table method, rats were divided into sham operation group, model group, low-dose sinomenine group, high-dose sinomenine group, 20 in each group. In addition to the sham operation group, the rat brain injury model was established by Feeney free falling impact method. Rats in low and high dose of sinomenine group were given sinomenine 30, 60 mg/kg by intraperitoneal injection, and the sham operation group and model group were injected intraperitoneally with the same volume of normal saline, once per day for 7 days. Histopathological changes in each group were observed by HE staining and electron microscope. Western blot and RT-PCR were used to detect AQP-4 and AQP-5 protein and gene expression in brain tissue. Results: The pathological results showed that the nerve cells in the model group were loosely arranged, disordered in hierarchy, some cells appear to have degenerated. The degeneration and necrosis of nerve cells in the low and high dose sinomenine group were less than those in the model group. Compared to the model group, the expression of AQP-4 (0.74 ± 0.13, 0.49 ± 0.11 vs. 1.30 ± 0.21), AQP-5 (0.98 ± 0.07, 0.45 ± 0.10 vs. 1.47 ± 0.18) in the low dose and high dose sinomenine group significantly decreased (P<0.05). The expression of AQP-4 (1.48 ± 0.18, 1.26 ± 0.12 vs. 2.04 ± 0.14), AQP-5 (1.31 ± 0.17, 1.20 ± 0.11 vs. 1.87 ± 0.15) mRNA in the low dose and high dose sinomenine group significantly decreased (P<0.05). Conclusions Sinomenine could alleviate cerebral injury by lowering the expression of AQP-4 and AQP-5.